# A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

> **NCT03825718** · EARLY_PHASE1 · COMPLETED · sponsor: **Hebei Yanda Ludaopei Hospital** · enrollment: 29 (actual)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** GC007F

## Key facts

- **NCT ID:** NCT03825718
- **Lead sponsor:** Hebei Yanda Ludaopei Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-17
- **Primary completion:** 2020-09-01
- **Final completion:** 2020-12-01
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2022-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03825718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03825718, "A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03825718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*